These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

596 related articles for article (PubMed ID: 33647002)

  • 1. Comparison chart: Drugs for Parkinson's disease.
    Med Lett Drugs Ther; 2020 Dec; 62(1613):e1-e9. PubMed ID: 33647002
    [No Abstract]   [Full Text] [Related]  

  • 2. Drugs for Parkinson's disease.
    Med Lett Drugs Ther; 2021 Feb; 63(1618):25-32. PubMed ID: 33647001
    [No Abstract]   [Full Text] [Related]  

  • 3. Istradefylline (Nourianz) for Parkinson's disease.
    Med Lett Drugs Ther; 2020 Feb; 62(1591):20-23. PubMed ID: 32022788
    [No Abstract]   [Full Text] [Related]  

  • 4. Opicapone (Ongentys) - a COMT inhibitor for Parkinson's disease.
    Med Lett Drugs Ther; 2021 Jan; 63(1615):3-5. PubMed ID: 33646998
    [No Abstract]   [Full Text] [Related]  

  • 5. Osmolex ER--another extended-release amantadine for Parkinson's disease.
    Med Lett Drugs Ther; 2018 Sep; 60(1555):148-150. PubMed ID: 30383732
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhaled levodopa (Inbrija) for Parkinson's disease.
    Med Lett Drugs Ther; 2019 May; 61(1572):73-74. PubMed ID: 31169799
    [No Abstract]   [Full Text] [Related]  

  • 7. Sublingual apomorphine (Kynmobi) for Parkinson's disease.
    Med Lett Drugs Ther; 2020 Oct; 62(1609):165-166. PubMed ID: 33429410
    [No Abstract]   [Full Text] [Related]  

  • 8. Drugs for Parkinson's disease.
    Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinson disease treatment in hospitals and nursing facilities: avoiding pitfalls.
    Ahlskog JE
    Mayo Clin Proc; 2014 Jul; 89(7):997-1003. PubMed ID: 24996235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The treatment of Parkinson's disease].
    Baumann CR; Waldvogel D
    Praxis (Bern 1994); 2013 Dec; 102(25):1529-35. PubMed ID: 24326048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological treatment of Parkinson's disease.
    Münchau A; Bhatia KP
    Postgrad Med J; 2000 Oct; 76(900):602-10. PubMed ID: 11009573
    [No Abstract]   [Full Text] [Related]  

  • 12. Other pharmacological treatments for motor complications and dyskinesias.
    Waters C
    Mov Disord; 2005; 20 Suppl 11():S38-44. PubMed ID: 15822104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
    Jankovic J; Stacy M
    CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contemporary Options for the Management of Motor Complications in Parkinson's Disease: Updated Clinical Review.
    Cabreira V; Soares-da-Silva P; Massano J
    Drugs; 2019 Apr; 79(6):593-608. PubMed ID: 30905034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.
    Deleu D; Northway MG; Hanssens Y
    Clin Pharmacokinet; 2002; 41(4):261-309. PubMed ID: 11978145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis.
    Binde CD; Tvete IF; Gåsemyr JI; Natvig B; Klemp M
    Eur J Clin Pharmacol; 2020 Dec; 76(12):1731-1743. PubMed ID: 32710141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.
    Pahwa R
    J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.
    Gray R; Patel S; Ives N; Rick C; Woolley R; Muzerengi S; Gray A; Jenkinson C; McIntosh E; Wheatley K; Williams A; Clarke CE;
    JAMA Neurol; 2022 Feb; 79(2):131-140. PubMed ID: 34962574
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 30.